Allergen peptide fragments and use thereof

Details Allergen peptide fragments and use thereof Allergen peptide fragments and use thereof

2005-09-14

2011-12-13

Rooney, Nora (Department: 1644)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C424S275100, C514S001100, C530S300000, C530S324000

Reexamination Certificate

active

08075897

ABSTRACT:
The present invention relates generally to in vivo methods and compositions designed for allergen specific immunotherapy. The compositions include contiguous overlapping peptide fragments which together form an entire amino acid sequence of an allergen.

REFERENCES:
patent: 4473495 (1984-09-01), Patterson
patent: 5124249 (1992-06-01), Khan et al.
patent: 5152980 (1992-10-01), Strom et al.
patent: 5723582 (1998-03-01), Ishizaka
patent: 5767075 (1998-06-01), Avruch et al.
patent: 5965709 (1999-10-01), Presta et al.
patent: 6042831 (2000-03-01), Beretta
patent: 6071522 (2000-06-01), Thomas et al.
patent: 6074673 (2000-06-01), Guillen
patent: 6395306 (2002-05-01), Cui et al.
patent: 6649166 (2003-11-01), Maillere et al.
patent: 2002/0193295 (2002-12-01), Calenoff et al.
patent: 2003/0165514 (2003-09-01), Spertini
patent: 2003/0211510 (2003-11-01), Henderson et al.
patent: 2004/0023291 (2004-02-01), Spertini
patent: 2005/0249742 (2005-11-01), Ruprecht et al.
patent: 2 341 389 (2000-03-01), None
patent: WO 99/18983 (1999-04-01), None
patent: WO 99/34826 (1999-07-01), None
patent: WO 00/15774 (2000-03-01), None
patent: WO 00/44887 (2000-08-01), None
patent: WO 01/88085 (2001-11-01), None
patent: WO 93/19178 (2003-09-01), None
Ebner et al.‘Identification of multiple T ell epitopes on Bet v I, the major pollen allergen, using specific T cell clones and overlapping peptides.’ J. Immunol. 150(3):1047-1054, 1993.
Ebner et al.‘Multiple T ell specificities for Bet v I, the major birch pollen allergen, within single individual. Studies using specifica T cell clones and overlapping peptides.’ Eur. J. Immunol. 23:1523-1527, 1993.
Sparholt et al. ‘Crossreactivity and T-cell epitope specificity of Bet v 1-specific T cells suggest the involvement of multiple isoallergens in sensitization to birch pollen.’ Clin. Exp. Allergy. 27(8):932-941, 1997.
Vrtala et al. ‘T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies.’ J. Immunol. 165:6653-6659, 2000.
Hoffmann-Sommergruber et al. ‘Genomic characterization of members of the Bet v 1 family: genes coding for allergens and pathogenesis-related proteins share intron positions.’ Gene 197:91-100, 1997.
Akdis et al, “Epitope-Specific T Cell Toleranace to Phosholipase A(2) in Bee Venom Immunotherapy and Recovery by IL-2 and IL-15 in Vitro,”J. Clin. Invest., 98:1676-83, 1996.
Akdis et al., “Role of Interleukin 10 in Specific Immunotherapy,”J. Clin. Invest., 102:98-106, 1998.
Akdis, et al, “IL-10-Induced Anergy in Peripheral T Cell and Reactivation by Microenvironmental Cytokines: Two Key Steps in Specific Immunotherapy,”FASEB J., 13:603-609, 1999.
Astori, et al., “Inducing Tolerance by Intranasal Administration of Long Peptides in Naive and Primed CBA/J Mice,”J. Immunol, 165: 3497-3505, 2000.
Attwood, T. “The Babel of Bioinformatics,”Science290 (5491): 471-473, 2000.
Banks, et al. in Piek T., ed. “Chemistry and Pharmacology of Honey-Bee Venom,”Venoms of the Hymenoptera, London: Academic Press, 329-416, 1986.
Bauer et al., “Modulation of the Allergic Immune Response in BALB/c Mice by Subcutaneolnjection of High Doses of the Dominant T Cell Epitope from the Major Birch Pollen Allergen Bet v 1,”Clin. Exp. Immunol., 107:536-41, 1997.
Briner et et, “Peripheral T-Cell Tolerance Induced in Naive and Primed Mice by Subcutaneolnjection of Peptides from the Major Cat Allergen Fel d I,”Proc. Natl. Acad. Sci. USA, 90:7608-12, 1993.
Burks, et al., “Mapping and Mutational Analysis of the IgE-Binding Epitopes on Ara h 1, a Legume Vicilin Protein and a Major Allergen in Peanut Hypersensitivity,”Eur. J. Biochem, 245:334-339, 1997.
Casari et al., “A Method to Predict Functional Residues in Proteins,”Structural Biology, 2(2):171-178, Feb. 1995.
Colman, “Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions,”A Structural View of Immune Recognition by Antibodies, Biomolecular Research Institute, 33-35, 1988.
De Waal et al., “Direct Effects of IL-10 on Subsets of Human CD4+ T Cell Clones and Resting T Cells. Specific Inhibition of IL-2 Production and Proliferation,”J. Immunol., 150:4754-65, 1993.
Faster et al., “Antagonistic Peptides Specifically Inhibit Proliferation, Cytokine Production, CD4OL Expression, and Help for IgE Synthesis by Der P 1-Specific Human T-cell Clones,”J. Allergy Clin. Immunol.101: 521-530, 1998.
Fellarth, et al., “Allergen-Specific T-Cell Tolerance Induction with Allergen-Derived Long Synthetic Peptides: Results of a Phase I Trial,”J. Allergy Clin. Immunol., 111(4): 854-861, 2003.
Ferreira et al., “Dissection of Immunoglobulin E and T Lymphocyte Reactivity of Isoforms of the Major Birch Pollen Allergen Bet v 1: Potential Use of Hypoallergenic Isoforms for Immunotherapy,”J. Exp. Med., 183:559-609, Feb. 1996.
Ferreira et al., “Modulation of IgE Reactivity of Allergens by Site-Directed Mutagenesis: Potential Use of Hypoallergenic Variants for Immunotherapy,”The FASEB Journal, 12:231-242, Feb. 1998.
Groux et al., “Interleukin-10 Induces a Long-Term Antigen-Specific Anergic State in Human CD4+ T Cells,”J. Exp. Med., 184:19-29, 1996.
Hansen et al., “Allergen-Specific Th1 Cells Fail to Counterbalance Th2 Cell-Induced Airway Hyperreactivity but Cause Severe Airway Inflammation,”J. Clin. Invest.103:175-83, 1999.
Haselden, et al., “Immunoglobulin E-Independent Major Histocompatibility Complex-Restricted T Cell Peptide Epitope-Induced Late Asthmatic Reactions,”J. Exp. Med., 189:1885-94, 1999.
Hoyne et al., “Regulation of House Dust Mite Responses by Intranasally Administered Peptide: Transient Activation of CD4+ T Cells Precedes the Development of Tolerance in Vivo,”Int. Immunol., 8:335-42, 1996.
Jilek, et al., “Antigen-Independent Suppression of the Allergic Immune Response to Bee Venom Phospholipase A2by DNA Vaccination in CBA/J Mice,”J. Immunol., 166: 3612-3621, 2001.
Jutel, et al., “Selective Restimulation of Antigen or Allergen Preactivated T Cells Using OKT3 F(ab)(2) Results in the Secretion of TH-1 or TH-2-Like Cytokine Patterns,”Clin. Experiment. Allergy, 25:1108-17, 1995.
Jutel, et al., “Bee Venom Immunotherapy Results in Decrease of IL-4 and IL-5 and Increase of IFN-γ Secretion in Specific Allergen-Stimulated T-Cell Cultures,”J. Immunol154: 4187-4194, 1995.
Kammerer, et al., “Modulation of T-Cell Response to Phospholipase A2and Phospholipase A2—Derived Peptides by Conventional Bee Venom Immunotherapy,”J. Allergy Clin Immunol., 100(1): 96-103, 1997.
Kammerer et al., “Delineation of PLA2Epitopes Using Short or Long Overlapping Synthetic Peptides: Interest for Specific Immunotherapy,”Clin. Exper. Allergy., 27: 1016-1026, 1997.
Kettner, et al., “IgE and T-Cell Responses to High-Molecular Weight Allergens from Bee Venom,”Clin. Experiment. Allergy, 29:394-401, 1999.
Kettner, et al., Api m 6: A New Bee Venom Allergen,J. Allergy Clin. Immunol., 107(5): 914-920, 2001.
King et al., “Antibody Responses to Bee Melittin (Api m 4) and Hornet Antigen 5 (Dol m 5) in Mice Treated with the Dominant T-Cell Epitope Peptides,”J. Allerg. Clin. Immunol., 101:397-403, 1998.
Larche, “Allergen-Derived T Cell Peptides in Immunotherapy,”Revue Francaise D'Allergologie et D'Immunologie Clinique 2003 France, 43(1):59-63, 2003.
Larche, “Peptide-Based Therapeutic Vaccines for Allergic and Autoimmune Diseases,”Nat. Med., 11(4 Suppl):S69-76, 2005.
Laver et al., “Epitopes on Protein Antigens: Misconceptions and Realities,”Cell, 61:553-556, May 1990.
Lesourd et al., “Hymenoptera Venom Immunotherapy: Relationships with Specific Antibody Responses,”J. Allergy Clin. Immunol., 83:563-71, 1989.
Ma

Affiliated with

Also associated with

Rating

Allergen peptide fragments and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Allergen peptide fragments and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Allergen peptide fragments and use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4270657